N-((2-Morpholin-4-yl-pyridin-3-yl)methyl)-6-(4-chlorophenyl)-pyrazine-2-carboxamide

ID: ALA1277700

Chembl Id: CHEMBL1277700

PubChem CID: 52950155

Max Phase: Preclinical

Molecular Formula: C21H20ClN5O2

Molecular Weight: 409.88

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C(NCc1cccnc1N1CCOCC1)c1cncc(-c2ccc(Cl)cc2)n1

Standard InChI:  InChI=1S/C21H20ClN5O2/c22-17-5-3-15(4-6-17)18-13-23-14-19(26-18)21(28)25-12-16-2-1-7-24-20(16)27-8-10-29-11-9-27/h1-7,13-14H,8-12H2,(H,25,28)

Standard InChI Key:  NEGLDDATOGSCRT-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA1277700

   N-((2-Morpholin-4-yl-pyridin-3-yl)methyl)-6-(4-chlorophenyl)-pyrazine-2-carboxamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 409.88

Molecular Weight (Monoisotopic): 409.1306

AlogP: 2.96

#Rotatable Bonds: 5

Polar Surface Area: 80.24

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.69

CX Basic pKa: 6.13

CX LogP: 2.63

CX LogD: 2.60

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.70

Np Likeness Score: -1.96

References

1. Scanio MJ, Shi L, Drizin I, Gregg RJ, Atkinson RN, Thomas JB, Johnson MS, Chapman ML, Liu D, Krambis MJ, Liu Y, Shieh CC, Zhang X, Simler GH, Joshi S, Honore P, Marsh KC, Knox A, Werness S, Antonio B, Krafte DS, Jarvis MF, Faltynek CR, Marron BE, Kort ME..  (2010)  Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.,  18  (22): [PMID:20965738] [10.1016/j.bmc.2010.09.057]

Source

Source(1):

• Scientific Literature